Equity Overview
Price & Market Data
Price: $7.65
Daily Change: +$0.03 / 0.39%
Range: $7.62 - $7.72
Market Cap: $470,943,680
Volume: 10,740
Performance Metrics
1 Week: 1.06%
1 Month: -7.19%
3 Months: 8.70%
6 Months: 0.66%
1 Year: -42.84%
YTD: 40.33%
Company Details
Employees: 353
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. The company offers ZURZUVAE, a neuroactive steroid positive allosteric modulator of GABA receptors targeting synaptic and extrasynaptic GABA receptors for the treatment of postpartum depression in adults. Its product pipeline also includes SAGE-324, a novel GABA receptor positive allosteric modulator for chronic oral dosing, including seizures in developmental and epileptic encephalopathies; and SAGE-319, an extrasynaptic-preferring GABA receptor positive allosteric modulator PAM for treating behavioral symptoms associated with neurodevelopmental disorders. In addition, the company is developing various product candidates, including SAGE-817 and SAGE-039 for the treatment of acute and chronic brain health disorders, including work on allosteric modulation of the GABA and NMDA receptor systems in the brain, as well as NMDA receptor negative allosteric modulator focusing on the treatments for neurodevelopmental disorders. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.